Molecular Endocrinology, Vol 8, 983-995, Copyright © 1994 by Endocrine Society

ARTICLES

Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor

T Shikone, MM Matzuk, E Perlas, MJ Finegold, KA Lewis, W Vale, A Bradley and AJ Hsueh
Department of Gynecology and Obstetrics, Stanford University Medical Center, California 94305-5317.

Inhibin-alpha-deficient mutant mice have been generated by a targeted deletion of the inhibin-alpha gene through homologous recombination in murine embryonic stem cells. Essentially all of the homozygous mutants develop gonadal sex cord-stromal tumors. To investigate their endocrine and proliferative characteristics, gonadal tumor cells were maintained in vitro. Cells from inhibin-alpha-deficient mice multiplied poorly; however, cells from mice deficient in both inhibin-alpha and p53 proliferated rapidly and showed higher saturation density and plating efficiency, thus allowing the establishment of clonal tumor cell lines. Although negligible estrogen and testosterone was produced by the clonal cells, high levels of progesterone were secreted. A clonal testis tumor cell line (inhibin-alpha/p53 deficient) showed no response to exogenous FSH, human CG (hCG), or inhibin A but exhibited a 6- to 8- fold increase in progesterone production in response to forskolin treatment. The stimulatory effect of forskolin was, however, partially blocked by activin treatment. Northern blot analysis revealed inhibin beta A and beta B mRNA expression in these cells. Furthermore, Western blot analyses indicated the secretion of the beta A-subunit protein. We further tested the role of activin on tumor cell growth. Treatment with follistatin, an activin-binding protein, inhibited tumor cell replication in a dose-dependent manner. In contrast, treatment with activin A stimulated tumor cell growth by itself and partially blocked follistatin action. Incorporation of thymidine into DNA of these cells was also stimulated by activin. In addition, treatment with antiactivin A serum inhibited tumor cell replication and blocked the stimulatory action of activin on cell growth. The activin action is likely mediated by specific receptors because cross-linking of [125]activin to the 50- 55 kilodalton type I and 75-80 kilodalton type II receptors was found using sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. Northern blot analysis also revealed follistatin mRNA expression in the tumor cells, suggesting these cells are related to granulosa cells. Our findings indicate that activin can act as an autocrine growth factor in stimulating the proliferation of gonadal tumor cell lines derived from inhibin-alpha and p53-deficient mice and inhibits progesterone production. These tumor cell lines are useful for studies on the regulation of gonadal cell proliferation and steroidogenesis as well as the signaling pathway mediating activin action.

This article has been cited by other articles:

				P. Ciarmela, E. Wiater, and W. Vale Activin-A in Myometrium: Characterization of the Actions on Myometrial Cells Endocrinology, May 1, 2008; 149(5): 2506 - 2516. [Abstract] [Full Text] [PDF]

				Q. Li, J. M. Graff, A. E. O'Connor, K. L. Loveland, and M. M. Matzuk SMAD3 Regulates Gonadal Tumorigenesis Mol. Endocrinol., October 1, 2007; 21(10): 2472 - 2486. [Abstract] [Full Text] [PDF]

				B. D. Looyenga and G. D. Hammer Genetic Removal of Smad3 from Inhibin-Null Mice Attenuates Tumor Progression by Uncoupling Extracellular Mitogenic Signals from the Cell Cycle Machinery Mol. Endocrinol., October 1, 2007; 21(10): 2440 - 2457. [Abstract] [Full Text] [PDF]

				Q. Li, R. Kumar, K. Underwood, A. E. O'Connor, K. L. Loveland, J. S. Seehra, and M. M. Matzuk Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein Mol. Hum. Reprod., September 1, 2007; 13(9): 675 - 683. [Abstract] [Full Text] [PDF]

				Y. Sidis, A. Mukherjee, H. Keutmann, A. Delbaere, M. Sadatsuki, and A. Schneyer Biological Activity of Follistatin Isoforms and Follistatin-Like-3 Is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin, and Bone Morphogenetic Proteins Endocrinology, July 1, 2006; 147(7): 3586 - 3597. [Abstract] [Full Text] [PDF]

				Y. Fujii, S. Kawakami, Y. Okada, Y. Kageyama, and K. Kihara Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E927 - E931. [Abstract] [Full Text] [PDF]

				P. J. Fuller, E. T. Zumpe, S. Chu, P. Mamers, and H. G. Burger Inhibin-Activin Receptor Subunit Gene Expression in Ovarian Tumors J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1395 - 1401. [Abstract] [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				S. C. Cipriano, L. Chen, K. H. Burns, A. Koff, and M. M. Matzuk Inhibin and p27 Interact to Regulate Gonadal Tumorigenesis Mol. Endocrinol., June 1, 2001; 15(6): 985 - 996. [Abstract] [Full Text] [PDF]

				H.-J. Huang, J. C. Wu, P. Su, O. Zhirnov, and W. L. Miller A Novel Role for Bone Morphogenetic Proteins in the Synthesis of Follicle-Stimulating Hormone Endocrinology, June 1, 2001; 142(6): 2275 - 2283. [Abstract] [Full Text] [PDF]

				S. C. Cipriano, L. Chen, T. R. Kumar, and M. M. Matzuk Follistatin Is a Modulator of Gonadal Tumor Progression and the Activin-Induced Wasting Syndrome in Inhibin-Deficient Mice Endocrinology, July 1, 2000; 141(7): 2319 - 2327. [Abstract] [Full Text] [PDF]

				T. Minegishi, T. Kameda, T. Hirakawa, K. Abe, M. Tano, and Y. Ibuki Expression of Gonadotropin and Activin Receptor Messenger Ribonucleic Acid in Human Ovarian Epithelial Neoplasms Clin. Cancer Res., July 1, 2000; 6(7): 2764 - 2770. [Abstract] [Full Text]

				N. Di Simone, H. A. Hall, C. Welt, and A. L. Schneyer Activin Regulates {beta}A-Subunit and Activin Receptor Messenger Ribonucleic Acid and Cellular Proliferation in Activin-Responsive Testicular Tumor Cells Endocrinology, March 1, 1998; 139(3): 1147 - 1155. [Abstract] [Full Text] [PDF]

				A. Kaipia, S. Y. Hsu, and A. J. W. Hsueh Expression and Function of a Proapoptotic Bcl-2 Family Member Bcl-XL/Bcl-2-Associated Death Promoter (BAD) in Rat Ovary Endocrinology, December 1, 1997; 138(12): 5497 - 5504. [Abstract] [Full Text] [PDF]

				C. K. Welt, G. Lambert-Messerlian, W. Zheng, W. F. Crowley Jr., and A. L. Schneyer Presence of Activin, Inhibin, and Follistatin in Epithelial Ovarian Carcinoma J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3720 - 3727. [Abstract] [Full Text] [PDF]

				A. Amsterdam and N. Selvaraj Control of Differentiation, Transformation, and Apoptosis in Granulosa Cells by Oncogenes, Oncoviruses, and Tumor Suppressor Genes Endocr. Rev., August 1, 1997; 18(4): 435 - 461. [Abstract] [Full Text] [PDF]

				L. Gnessi, A. Fabbri, and G. Spera Gonadal Peptides as Mediators of Development and Functional Control of the Testis: An Integrated System with Hormones and Local Environment Endocr. Rev., August 1, 1997; 18(4): 541 - 609. [Abstract] [Full Text] [PDF]

				T. J. Kotlar, R. H. Young, C. Albanese, W. F. Crowley Jr., R. E. Scully, and J. L. Jameson A Mutation in the Follicle-Stimulating Hormone Receptor Occurs Frequently in Human Ovarian Sex Cord Tumors J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1020 - 1026. [Abstract] [Full Text] [PDF]

				A. C. Chen and L. J. Gudas An Analysis of Retinoic Acid-induced Gene Expression and Metabolism in AB1 Embryonic Stem Cells J. Biol. Chem., June 21, 1996; 271(25): 14971 - 14980. [Abstract] [Full Text] [PDF]